The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Δημοσίευση

Immunization with recombinant prion protein leads to partial protection in a murine model of TSEs through a novel mechanism.

TitleImmunization with recombinant prion protein leads to partial protection in a murine model of TSEs through a novel mechanism.
Publication TypeJournal Article
Year of Publication2013
AuthorsXanthopoulos, K., Lagoudaki R., Kontana A., Kyratsous C., Panagiotidis C., Grigoriadis N., Yiangou M., & Sklaviadis T.
JournalPLoS One
Volume8
Issue3
Paginatione59143
Date Published2013
ISSN1932-6203
KeywordsAnimals, Dendritic Cells, Follicular, Disease Models, Animal, Female, Immunity, Humoral, Immunization, Mice, Mice, Inbred C57BL, Prion Diseases, Prions, Recombinant Proteins, Survival Analysis
Abstract

Transmissible spongiform encephalopathies are neurodegenerative diseases, which despite fervent research remain incurable. Immunization approaches have shown great potential at providing protection, however tolerance effects hamper active immunization protocols. In this study we evaluated the antigenic potential of various forms of recombinant murine prion protein and estimated their protective efficacy in a mouse model of prion diseases. One of the forms tested provided a significant elongation of survival interval. The elongation was mediated via an acute depletion of mature follicular dendritic cells, which are associated with propagation of the prion infectious agent in the periphery and in part to the development of humoral immunity against prion protein. This unprecedented result could offer new strategies for protection against transmissible encephalopathies as well as other diseases associated with follicular dendritic cells.

DOI10.1371/journal.pone.0059143
Alternate JournalPLoS ONE
PubMed ID23554984
PubMed Central IDPMC3598700

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.